Next Article in Journal
Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir
Previous Article in Journal
A Plant Worthy of Further Study—Volatile and Non-Volatile Compounds of Portenschlagiella ramosissima (Port.) Tutin and Its Biological Activity
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 15
Issue 12
10.3390/ph15121455
Review Report
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS

Pharmaceuticals 2022, 15(12), 1455; https://doi.org/10.3390/ph15121455
by Meng Li 1, Qing-Song Zhang 1, Xin-Ling Liu 1, Hui-Ling Wang 2 and Wei Liu 1,*
Reviewer 1:
Kamil Jurowski
Reviewer 2:
Cody Peer
Pharmaceuticals 2022, 15(12), 1455; https://doi.org/10.3390/ph15121455
Submission received: 28 October 2022 / Revised: 18 November 2022 / Accepted: 21 November 2022 / Published: 24 November 2022
(This article belongs to the Section Pharmacology)

Round 1

Reviewer 1 Report

The submitted article ‘Adverse Events Associated with Nirmatrelvir/ritonavir:
A Pharmacovigilance Analysis Based on FAERS’ is interesting and good article. This is a kind of rare studies, hence is very desire. It will be appropriate for PHARMACEUTICALS (MDPI). Below I pointed most of mistakes and matters for explanation.

1.      In introduction the emphasis should be placed on justification

2.      In introduction, there is a lack basic information about application of ritonavir in AIDS treatment – this is a big disadvantage; please cite also PMID: 20836579 and PMID: 28614778

3.      The good idea should be summary as graphical workflow in introduction

4.      Conclusion part should be more informative (more details, perhaps in brackets?)

5.      Please include advances and disadvantages of your studies in conclusions

I totally agree that this is very important subject, and it is very important for publication in MDPI. I will recommend this article for publication in PHARMACEUTICALS after minor revision.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

By utilizing data obtained from the FDA adverse event reporting system, the authors preformed a disproportionality analysis to evaluate the risk of adverse events resulting from nirmatrelvir/ritonavir in the treatment of patients with COVID-19. Their principal finding demonstrated a significant signal for the association of disease recurrence and treatment with nirmatrelvir/ritonavir (as opposed to all other treatments, which had no signal).

 

 

General comments:

·      The manuscript was polished, concise, and well written.

·      Results were supported by using subset(age/gender) and sensitivity (AE reporter only healthcare professionals) analysis.

o   As FAERS is a spontaneous reporting system, confirmation with an external database would have demonstrated that the results were not a product of or biased by the reporting system.

·      Data interpretational was rational

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop